Ligand validation:6GUX

RET: RETINAL

RET is a Ligand Of Interest in 6GUX designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6GUX_RET_A_300	92%	13%	0.084	0.975	2.4	1.54	2	6	0	0	100%	0.6667
6S6C_RET_A_300	94%	19%	0.072	0.972	2.41	1.07	4	3	1	0	100%	0.2381
6S63_RET_A_300	86%	16%	0.09	0.957	2.35	1.37	4	3	0	0	100%	0.4762
6GUZ_RET_A_300	58%	17%	0.156	0.935	2.41	1.21	5	1	0	0	100%	0.2857
7ZY3_RET_A_300	29%	3%	0.207	0.864	4.17	2.01	13	8	0	0	100%	0.4762
6GUY_RET_A_300	15%	2%	0.253	0.817	4.69	2.03	14	10	0	0	100%	19.05
3UTY_RET_A_301	100%	5%	0.028	0.992	2.48	2.7	6	12	2	0	100%	0.9524
3UTX_RET_B_301	100%	6%	0.042	0.988	2.42	2.7	5	12	4	0	100%	0.9524
7XJE_RET_A_301	99%	6%	0.048	0.983	1.99	2.98	4	14	1	0	100%	0.9524
5G28_RET_A_1268	97%	23%	0.051	0.968	1.29	1.84	3	5	0	0	100%	0.9524
7XJC_RET_A_301	97%	10%	0.067	0.98	1.93	2.43	2	14	0	0	100%	0.7752

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.